Воздействие остаточных клональных плазменных клеток в фазе S во время аутологической трансплантации стволовых клеток на клинические результаты.

Introduction

autologous stem cell transplant (ASCT) remains an important element of the treatment paradigm for patients with multiple myeloma (MM), offering deeper responses and improved progression free survival (PFS) [ 1 – 4 ]. However, some patients experience suboptimal outcomes following ASCT. Studies have shown that early relapses, occurring within one to two years post-ASCT, are associated with inferior outcomes [ 5 ]. Some pre and post- transplant prognostic factors that have been associated with earlier relapses following ASCT include the baseline presence of high-risk fluorescence in situ hybridization (HR-FISH) cytogenetics, higher international staging system (ISS) stage, elevated LDH (Lactate dehydrogenase) levels, higher number of prior lines of therapy and achieving less than a complete response (CR) after ASCT [ 6 , 7 ]. However, there are limited studies addressing factors present at the time of ASCT that may influence relapse risk and survival outcomes in patients with MM. Our group has previously demonstrated that a higher percentage of plasma cell labeling index (PCLI) at the time of ASCT is associated with earlier relapses following ASCT [ 8 ]. The PCLI measures the percentage of plasma cells actively synthesizing DNA, reflecting their proliferative activity and providing insight into the biology of plasma cells. However, the use of PCLI has been limited due to its labor-intensive nature. As a result, the plasma cell proliferation (PCPRO) test, a multiparametric flow cytometry-based assay, has replaced PCLI in clinical practice. The PCPRO test offers a more convenient method to quantify the proportion or percentage of monotypic plasma cells in the S-phase, effectively capturing their proliferation rate [ 9 ]. Recently, our group evaluated the impact of S-phase% at the time of MM diagnosis on outcomes, considering more recent prognostic stratification and treatment strategies. It was observed that a higher S-phase% (i.e., S phase% ≥2) at diagnosis was associated with an inferior PFS and overall survival (OS) in multivariate analysis containing conventional prognostic features [ 10 ].

In this study, we aim to investigate whether the S-phase% of the residual plasma cells in the bone marrow at the time of ASCT retains its prognostic value in predicting for a shorter PFS and OS outcomes after ASCT. We seek to identify a subset where the benefit of ASCT is so limited that alternative strategies should be considered in the first line.

Methods

This retrospective study included patients diagnosed with MM between January 1, 2013, and August 31, 2024, who underwent ASCT within one year of diagnosis at the Mayo Clinic in Rochester, MN. The study was approved by the institutional review board (IRB #24-009552). As shown in (Fig. 1 ), of 2,348 patients identified, 1,157 met the inclusion criteria. After excluding 21 patients without available S-phase data, 1,136 patients were included in the final analysis. Fig. 1 CONSORT diagram illustrating patient selection for analysis. From a total of 2348 patients with multiple myeloma, exclusions were made for those not undergoing ASCT within 1 year of diagnosis (n = 1191) and those lacking S-phase data (n = 21). The final cohort of 1136 was categorized as S-phase <2% (n = 372), S-phase ≥2% (n = 142), and S-phase not assessable (n = 622). ASCT autologous stem cell transplantation.

Flow cytometric immunophenotyping was performed using the following antibodies: CD19, CD38, CD45, CD138, cytoplasmic kappa and lambda immunoglobulin, and DAPI (4’,6-diamidino-2-phenylindole) as previously described [ 9 ]. The plasma cell clonality was determined through demonstrating CD38 and CD138 positivity, absence of CD19/CD45 expression, immunoglobulin light chain restriction, and/or ploidy difference by DAPI staining. The percentage of clonal plasma cells in S-phase was determined by measuring the proportion of cells with DNA content between the G0/G1 and G2/M peaks.

A minimum of 300 abnormal plasma cells is required for reliable S-phase assessment using the PCPRO assay; samples with fewer events were considered non-assessable [ 11 ], which usually reflects patients with a CR or better after induction therapy.

Following previously established cutoffs [ 12 ], patients were stratified into three groups: S-phase <2%, S-phase ≥2%, and non-assessable. A secondary analysis further divided assessable cases into four subgroups: <2%, 2–4.9%, 5–9.9%, and ≥10%.

High-risk cytogenetic abnormalities (HRCA) by FISH included del(17p), t(4;14), t(14;16), t(14;20), and 1q21 gain/amplification. PFS was defined from the date of transplant to relapse, progression [ 13 ], or death, OS from transplant to death from any cause, with censoring at the date of last follow-up.

Categorical variables were compared using the chi-square or Fisher’s exact test, and continuous variables using the Wilcoxon rank-sum test. PFS and OS were estimated using the Kaplan–Meier method and compared using log-rank tests. Univariable and multivariable Cox proportional hazards models were used to assess the prognostic impact of S-phase%, while adjusting for age, ISS stage, serum creatinine, high-risk cytogenetics, depth of response at ASCT, and post-transplant maintenance therapy. All analyses were performed using JMP software (version 10; SAS Institute) and R software (version 4.2.2; R Foundation for Statistical Computing).

Results

A total of 1136 patients who underwent ASCT within one year of MM diagnosis were identified. Baseline patient characteristics are summarized in Table 1 . Compared to patients with an S-phase <2%, those with an S-phase ≥2% were more likely to have high-risk cytogenetic abnormalities (59.8% vs 31.9%, P < 0.0001), ISS stage III disease (31.6% vs 19.3%, P = 0.0048), and creatinine ≥2 mg/dL (18.3% vs 8.6%, P = 0.0044). Additionally, patients with an S-phase ≥2% had a higher rate of achieving very good partial response (VGPR) or better at the time of ASCT (58.4% vs 36.8%, P < 0.0001) with no difference in the likelihood to receive maintenance therapy post-transplant (13.4% vs 11.3, P = 0.5339). Table 1 Demographic and clinical features—all patients. Characteristic All n = 1136 S-Phase <2% n = 372 S-Phase ≧2% n = 142 No/few monotypic plasma cells n = 622 a p -value Age, median (IQR) 63 (56–68) 63 (56–67) 62.5 (57–69) 63 (56–68) 0.27 Sex, % male 59.2 60.7 62.6 57.5 0.76 Any HRCA, n (%) 508(44.7) 119(31.9) 85(59.8) 304(48.8) <0.0001 Deletion 17p 146(12.8) 31(8.3) 35(24.6) 80(12.8) <0.0001 1q gain/amplification 370 (32.5) 86(23.1) 58(40.8) 226(36.3) <0.0001 t(4:14) 114(10) 16(4.3) 18(12.6) 80(12.8) <0.0009 t(14:16) 44(3.8) 6(1.6) 9(6.3) 29(4.6) 0.0057 t(14:20) 15(1.3) 3(0.8) 5(3.5) 7(1.1) 0.0337 Unknown 119(10.4) 20(5.3) 15(10.5) 84(13.5) ISS Stage, n (%) Low (I) 331(29.1) 132(35.4) 31(21.8) 168(27) 0.0048 b Intermediate (II) 312(27.4) 100(26.8) 42(29.5) 170(27.3) High (III) 272(23.9) 72(19.3) 45(31.6) 155(24.9) Unknown 221(19.4) 68(18.2) 24(16.9) 129(20.7) Cr ≧2 mg/dl, n (%) 155(13.6) 32(8.6) 26(18.3) 97(15.5) 0.0044 Induction therapy n (%) Doublet 31(2.7) 19(5.1) 8(5.6) 4(0.6) 0.6287 c Triplet 805(70.8) 277(74.4) 102(71.8) 426(68.4) Quadruplet 300(26.4) 76(20.4) 32(22.5) 192(30.8) Unknown 0 0 0 0 Disease response at transplantation, n (%) <VGPR 342(30) 235(63.1) 59(41.5) 48(7.7) <0.0001 ≧VGPR 787(69.2) 137(36.8) 83(58.4) 567(91.1) Unknown 7(0.6) 0 0 7(1.1) Maintenance therapy n (%) No maintenance d 89(7.8) 42(11.3) 19(13.4) 28(4.5) 0.5339 IMiD 568(50) 198(53.2) 53(37.3) 317(50.9) PI 159(13.9) 44(11.8) 19(13.3) 96(15.4) IMiD+PI 170(14.9) 38(10.2) 28(19.7) 104(16.7) Anti CD38-based 113(9.9) 38(10.2) 13(9.1) 62(9.9) Unknown 10(0.8) 4(1) 0 6(0.9 HRCA high-risk cytogenetic abnormalities, ISS International Staging System, IQR interquartile range, Cr creatinine, PI proteasome inhibitor, IMiD immunomodulatory drug, ASCT autologous stem cell transplantation, VGPR very good partial response, NR not reached. a P -values compare groups with S-phase <2% versus S-phase ≥2%. b P -value calculated between ISS stage I/II versus III among patients with available S-phase. c P -value calculated between doublet/triplet versus quadruplet induction therapy among patients with available S-phase. d Patients who relapsed within 100 days and didn’t get maintenance therapy were excluded. 8 patients from the <2% group and 10 from the ≥2% and 9 from the no/few monotypic plasma cells group.

At a median follow-up of 41 months (interquartile range [IQR], 21–63); the median PFS was 26 months (95% CI: 17–35) in the S-phase ≥2% group compared to 47 months (95% CI: 39–58) in the S-phase <2% group (HR 1.7; 95% CI:1.3-2.3) ( P < 0.0001) (Fig. 2A ). The median OS was 57 months (95% CI: 42–NR) in the S-phase ≥2% group, while it was NR (95% CI: 110–NR) in the S-phase <2% group (HR 3.3; 95% CI: 2.3–4.8) ( P < 0.0001) (Fig. 2B ). In multivariate analysis, adjusting for age, ISS stage, serum creatinine level, high-risk FISH, response at ASCT, and maintenance therapy, S-phase ≥2% remained an independent predictor of inferior PFS (HR, 1.4; 95% CI: 1.0–2.3; P = 0.0266) (Table 2 ). Similarly; OS remained inferior in the group with S-phase ≥2% (HR, 1.8; 95% CI: 1.1–2.9; P = 0.0191) in multivariate analysis (Table 3 ). Fig. 2 Kaplan–Meier survival analysis in patients with multiple myeloma who underwent ASCT within one year of diagnosis, stratified by S-phase percentage at the time of transplantation <2% and S-phase ≥2%. A PFS. B OS. ASCT autologous stem cell transplantation, MM multiple myeloma, PFS progression-free survival, OS overall survival, NR not reached. Table 2 Univariable and multivariable analyses for progression-free survival (PFS). Patient attribute HR (95% CI) P Value Univariable analysis S-phase ≥2% 1.7 (1.3–2.3) <0.0001 Multivariable analysis S-phase ≥2% 1.4 (1.0–2.3) 0.0266 Age >65 years 1.4 (1.0–1.9) 0.0299 ISS stage III 1.4 (0.9–2.0) 0.0912 Serum creatinine ≥2 mg/dL 0.9 (0.5–1.5) 0.7684 High-risk FISH 1.6 (1.2–2.3) 0.0014 Maintenance therapy (Yes) 0.4 (0.3–0.6) <0.0001 Response at ASCT (<VGPR) 1.2 (0.8–1.7) 0.1928 Bold values indicate results that are statistically significant, defined as P < 0.05. Table 3 Univariable and multivariable analyses for overall survival (OS). Patient attribute HR (95% CI) P Value Univariable analysis S-phase ≥2% 3.3 (2.3–4.8) <0.0001 Multivariable analysis S-phase ≥2% 1.8 (1.1–2.9) 0.0191 Age >65 years 2.2 (1.4–3.6) 0.0005 ISS stage III 1.2 (0.6–2.2) 0.05001 Serum creatinine ≥2 mg/dL 1.5 (0.7–3.1) 0.2365 High-risk FISH 2.2 (1.3–3.7) 0.0017 Maintenance therapy (Yes) 0.3 (0.2–0.5) <0.0001 Response at ASCT (<VGPR) 0.7 (0.4–1.2) 0.2536 Bold values indicate results that are statistically significant, defined as P < 0.05.

We also compared outcomes between patients with an S-phase <2%, ≥2% and those with non-assessable S-phase. Median PFS was 26 months (95% CI: 17–35) for patients with S-phase ≥2%, 47 months (95% CI: 39–58) for patients with S-phase <2%, and 104 months (95% CI: 95–NR) for patients with non-assessable S-phase ( P < 0.0001). The median OS was 57 months (95% CI: 42–NR) for patients with S-phase ≥2%, NR with a lower bound of 110 months (95% CI: 110–NR) for patients with S-phase <2%, and NR (95% CI: NR–NR) for patients with non-assessable S-phase ( P < 0.0001) (Supplementary Figs. 1 and 2 ).

After subcategorizing patients with assessable S-phase results into groups with S-phase <2% (n = 372), 2–4.9% (n = 105), 5–9.9% (n = 27), and ≥10% (n = 10), PFS and OS were most inferior in the subgroup with an S-phase% of ≥10%. The median PFS and OS were 13 months (95% CI: 7–35) and 34 months (95% CI: 13–NR) respectively in the group with a S-phase% of 5–9.9% (Fig. 3A, B ). The group with an S-phase ≥10% had a median PFS and OS of 3.5 months (95% CI: 1–6) and 9.5 months (95% CI: 3–26), respectively. Fig. 3 Kaplan–Meier survival analysis in patients with multiple myeloma who underwent ASCT within one year of diagnosis, stratified by S-phase percentage at the time of transplantation (<2%, 2–4.9%, 4.9–9.9%, and ≥10%). A PFS. B OS. ASCT autologous stem cell transplantation, MM multiple myeloma, PFS progression-free survival, OS overall survival, NR not reached.

Discussion

Under normal physiological conditions, polyclonal plasma cells are terminally differentiated and non-proliferative [ 14 ]. However, in MM, clonal plasma cells may re-acquire proliferative capacity through molecular alterations, leading to more aggressive disease behavior [ 15 ]. Increased proliferative activity, as captured by the S-phase% measurement, has been associated with worse clinical outcomes [ 16 ]. We previously showed that S-phase% assessment by PCPRO test at MM diagnosis carries prognostic significance in this population [ 10 ]. Our study extended the utility of assessing the S-phase% of monoclonal plasma cells measured by the PCPRO test at the time of ASCT as a prognostic tool to predict post-ASCT outcomes in MM patients, as we demonstrated inferior PFS and OS outcomes in patients who had high S-phase% at the time of ASCT. These findings align with an earlier study utilizing the PCLI test, a slide-based, labor-intensive method for estimating plasma cell proliferation, which also demonstrated prognostic relevance at the time of ASCT [ 8 ]. Importantly, the PCPRO utilized to measure S-phase% offers a more accessible and scalable alternative to PCLI [ 17 – 19 ]. Our results reinforce the clinical value of S-phase analysis in the modern therapeutic landscape, which has been transformed by the integration of triplet and quadruplet induction regimens and the widespread use of CD38-targeted monoclonal antibodies [ 20 – 22 ]. Also, it shows its significance in the current understanding of the prognostic impact of cytogenetic abnormalities [ 23 ].

While the PCPRO assay is not yet widely adopted in general practice, its flow-based methodology makes it considerably more practical than older techniques such as PCLI. This highlights the importance of incorporating S-phase assessment into prospective studies, which could support broader use in routine pre-transplant evaluations.

In the modern era, despite the ongoing and rapidly evolving treatment options, the role of ASCT in upfront consolidation after induction therapy remains the standard of care irrespective of baseline poor prognostic risk factors for early relapse. However, the most striking and clinically relevant finding of our study is that patients with an S-phase ≥5%, and especially those with ≥10%, experienced dramatically inferior outcomes after ASCT, with median PFS of only 13 and 3.5 months, respectively. This identifies a functionally high-risk group that may derive little or no benefit from standard ASCT consolidation. Recognizing such patients before transplant could profoundly impact treatment planning. Many patients confronted with median PFS < 1 year may elect to forgo ASCT, concluding that the impact on quality of life and geographic relocation to a transplant center for up to 6 weeks would not be justified for this short period of PFS. In the context of expanding options, including quadruplet induction regimens and novel immunotherapies, these findings support considering alternative frontline strategies or enrollment in clinical trials for patients identified with highly proliferative disease at the time of ASCT evaluation.

Indeed, chimeric antigen receptor (CAR) T-cell therapy and T-cell engagers are being studied at the frontline treatment of patients with newly diagnosed MM ( NCT05257083 , NCT05695508 ) and could potentially be standard options for these difficult to treat subgroups of patients.

A major strength of our study is the large patient cohort. Although a significant proportion of patients did not have assessable S-phase at the time of ASCT, primarily due to an insufficient number of abnormal plasma cells (fewer than 300 events required for PCPRO analysis at Mayo Clinic), we addressed this subset of patient by comparing their clinical outcomes to those with both low ( < 2%) and high ( ≥ 2%) S-phase fractions. Outcomes in these patients with no assessable S-Phase% were the most favorable, supporting the notion that they represent a biologically favorable group. This would be expected given the fact that fewer than 300 plasma cells by flowcytometry reflects the deepest response to anti-myeloma induction therapy and one would anticipate a better outcome than patients with greater than 300 plasma cells presenting for consideration for ASCT.

This study’s limitations include its retrospective nature. Additionally, the relatively small number of patients with extremely high S-phase values (≥10%) limited the statistical power for some subgroup analyses.

In conclusion, incorporating flow-based S-phase% assessment of residual clonal plasma cells in the bone marrow at the time of ASCT into routine pre-transplant evaluation could enhance individualized treatment planning. Notably, identifying patients with S-phase ≥5% — who had exceptionally poor outcomes and represent a functionally high-risk group — could directly inform decisions to consider alternative upfront strategies, deferring stem cell transplantation given the short duration of PFS. Future prospective studies are warranted to validate these observations and to define optimal management approaches for patients with highly proliferative disease.

Supplementary information

SUPPLEMENT

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s41408-025-01349-y.

Acknowledgements

Research reported in this publication was supported by Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Number R01 CA254961 (WIG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

TH, MAG, and WIG came up with the conception and design of the study. TH, SAAY, DGP, and AMO collected and assembled data. TH and SS analyzed the data. TH drafted the paper. TH, DGP, SAAY, AMO, SS, SKK, AD, SZ, DJ, HO, PH, GO, FKB, DD, SRH, PK, NL, JC, NA, MB, EM, RW, TVK, RSG, YL, SVR, WIG, and MAG contributed to data interpretation, provided expert input, and approved the final version of the paper.

Data availability

Data are available upon reasonable request.

Competing interests

MAG reports personal fees from Ionis/Akcea, honorarium from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from AbbVie and Arcellx, fees from Johnson & Johnson, Honoraria from Astra Zeneca, Medscape, Dava Oncology, Alexion. All other authors declare no competing interests.

Ethics approval and consent to participate

All methods were performed in accordance with relevant guidelines and regulations. This study was approved by the Mayo Clinic Institutional Review Board (IRB #24-009552). Informed consent was obtained from all participants in the cohort.

References

1. Richardson PG Jacobus SJ Weller EA Hassoun H Lonial S Raje NS Triplet therapy, transplantation, and maintenance until progression in myeloma N Engl J Med 2022 387 132 47 10.1056/NEJMoa2204925 35660812 PMC10040899 Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–47. 35660812 10.1056/NEJMoa2204925 PMC10040899

2. Attal M Lauwers-Cances V Hulin C Leleu X Caillot D Escoffre M Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma N Engl J Med 2017 376 1311 20 10.1056/NEJMoa1611750 28379796 PMC6201242 Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. 28379796 10.1056/NEJMoa1611750 PMC6201242

3. Mo CC, Hartley-Brown MA, Midha S, Richardson PG. Upfront or deferred autologous stem cell transplantation for newly diagnosed multiple myeloma in the era of triplet and quadruplet induction and minimal residual disease/risk-adapted therapy. Cancers (Basel). 2023;15:5709. 10.3390/cancers15245709 PMC10741557 38136255

4. Ebraheem M Kumar SK Dispenzieri A Jevremovic D Buadi FK Dingli D Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy Transplant Cell Ther 2022 28 760.e1 e5 10.1016/j.jtct.2022.07.030 35940527 PMC9674950 Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, et al. Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy. Transplant Cell Ther. 2022;28:760.e1–e5. 35940527 10.1016/j.jtct.2022.07.030 PMC9674950

5. Corre J Montes L Martin E Perrot A Caillot D Leleu X Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk Haematologica 2020 105 e480 3 10.3324/haematol.2019.236588 33054068 PMC7556617 Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020;105:e480–3. 33054068 10.3324/haematol.2019.236588 PMC7556617

6. Zhou H Jian Y Du J Liu J Zhang Z Yang G Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era Cancer Med 2023 12 9085 96 10.1002/cam4.5630 37021846 PMC10166899 Zhou H, Jian Y, Du J, Liu J, Zhang Z, Yang G, et al. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era. Cancer Med. 2023;12:9085–96. 37021846 10.1002/cam4.5630 PMC10166899

7. Martinez-Lopez J Blade J Mateos MV Grande C Alegre A García-Laraña J Long-term prognostic significance of response in multiple myeloma after stem cell transplantation Blood 2011 118 529 34 10.1182/blood-2011-01-332320 21482708 Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118:529–34. 21482708 10.1182/blood-2011-01-332320

8. Kumar S Mahmood ST Lacy MQ Dispenzieri A Hayman SR Buadi FK Impact of early relapse after auto-SCT for multiple myeloma Bone Marrow Transplant 2008 42 413 20 10.1038/bmt.2008.180 18587435 Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2008;42:413–20. 18587435 10.1038/bmt.2008.180

9. Aljama MA Sidiqi MH Lakshman A Dispenzieri A Jevremovic D Gertz MA Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma Blood Adv 2018 2 3149 54 10.1182/bloodadvances.2018024794 30463914 PMC6258920 Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2:3149–54. 30463914 10.1182/bloodadvances.2018024794 PMC6258920

10. Zanwar S Jevremovic D Kapoor P Olteanu H Buadi F Horna P Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma Blood Cancer J 2025 15 20 10.1038/s41408-025-01232-w 39966346 PMC11836398 Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 2025;15:20. 39966346 10.1038/s41408-025-01232-w PMC11836398

11. Laboratories MC. Plasma cell proliferation, bone marrow. 2024. https://www.mayocliniclabs.com/test-catalog/overview/61654 .

12. Mellors PW Binder M Ketterling RP Greipp PT Baughn LB Peterson JF Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma Blood Adv 2020 4 2236 44 10.1182/bloodadvances.2019001275 32442300 PMC7252538 Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4:2236–44. 32442300 10.1182/bloodadvances.2019001275 PMC7252538

13. Kumar S Paiva B Anderson KC Durie B Landgren O Moreau P International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol 2016 17 e328 46 10.1016/S1470-2045(16)30206-6 27511158 Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46. 27511158 10.1016/S1470-2045(16)30206-6

14. Calame KL Plasma cells: finding new light at the end of B cell development Nat Immunol 2001 2 1103 8 10.1038/ni1201-1103 11725300 Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2:1103–8. 11725300 10.1038/ni1201-1103

15. Bergsagel PL Kuehl WM Molecular pathogenesis and a consequent classification of multiple myeloma J Clin Oncol 2005 23 6333 8 10.1200/JCO.2005.05.021 16155016 Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–8. 16155016 10.1200/JCO.2005.05.021

16. Greipp PR Lust JA O’Fallon WM Katzmann JA Witzig TE Kyle RA Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 1993 81 3382 7 10.1182/blood.V81.12.3382.3382 8507875 Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–7. 8507875

17. Greipp PR Kumar S Plasma cell labeling index Methods Mol Med 2005 113 25 35 15968092 10.1385/1-59259-916-8:25 Greipp PR, Kumar S. Plasma cell labeling index. Methods Mol Med. 2005;113:25–35. 15968092 10.1385/1-59259-916-8:25

18. Kumar S Rajkumar SV Greipp PR Witzig TE Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments Am J Hematol 2004 77 7 11 10.1002/ajh.20125 15307099 Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol. 2004;77:7–11. 15307099 10.1002/ajh.20125

19. Steensma DP Gertz MA Greipp PR Kyle RA Lacy MQ Lust JA A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death Blood 2001 97 2522 3 10.1182/blood.V97.8.2522 11290618 Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97:2522–3. 11290618 10.1182/blood.v97.8.2522

20. Durie BGM Hoering A Abidi MH Rajkumar SV Epstein J Kahanic SP Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial Lancet 2017 389 519 27 10.1016/S0140-6736(16)31594-X 28017406 PMC5546834 Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27. 28017406 10.1016/S0140-6736(16)31594-X PMC5546834

21. Sonneveld P Dimopoulos MA Boccadoro M Quach H Ho PJ Beksac M Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma N Engl J Med 2024 390 301 13 10.1056/NEJMoa2312054 38084760 Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13. 38084760 10.1056/NEJMoa2312054

22. Voorhees PM Kaufman JL Laubach J Sborov DW Reeves B Rodriguez C Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Blood 2020 136 936 45 10.1182/blood.2020005288 32325490 PMC7441167 Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45. 32325490 10.1182/blood.2020005288 PMC7441167

23. Sonneveld P Avet-Loiseau H Lonial S Usmani S Siegel D Anderson KC Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Blood 2016 127 2955 62 10.1182/blood-2016-01-631200 27002115 PMC4920674 Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62. 27002115 10.1182/blood-2016-01-631200 PMC4920674